engleski

Long-term thyroxine treatment and osteoporosis

The aim of this study was to determine whether long-term thyroxine treatment is a risk factor in the case of osteoporosis. A selected group of women in premenstrual period (N=19), and a selected group of men (N=9) suffering from differentiated thyroid gland carcinoma in the average age of 39.0+/-8.0 years and 41.8+/-10.0 years were examined. To all of them, the total thyreoidectomy was done and the thyroxine suppression therapy was introduced. The duration of the suppression therapy from the beginning of the research, for the female examinees, amounted 9.6+/-6, 4 years, and8, 1+/-6.0 years for the male examinees. The prospective study of the bone densitometry was done to all of examinees using the method of dual photon X-ray absorptiometry (DXA) of the spine and of the femoral neck, and also by the method of one-photon absorptiometry (SPA) of the distal radius. Statistically significant loss of bone tissue was registered only on the distal radius consering male examinees (p<0, 05). On the lumbar part of the spine and femoral neck, only a minor bone loss was registred in the small number of examinees, and it was of no statistical relevance nor for male or for female examinees. It is necessary to prolong the time of observation in the prospective studies, as well as to increase the number of examinees, in order to define relative risk involved in thyroxine suppression treatment of osteoporosis. Bone densitometry should already be included in diagnostical and therapy procedure, in order to discover persons with largest risk for osteoporosis on time, and to be able to undertake preventive treatment.

thyroxine suppressive therapy; bone densitometry; thyroid carcinoma; osteopenia; prospective study

nije evidentirano